Are patients in clinical trials representative of the general population? Dose intensity and toxicities associated with FE100C-D chemotherapy in a non-trial population of node positive breast cancer patients compared with PACS-01 trial group.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ejca.2010.10.001PMID 21094038
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High rate of febrile neutropenia in patients with operable breast cancer receiving docetaxel and cyclophosphamide.

  2009cited by this paper
• Sequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trial

  2009cited by this paper
• Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.

  2006cited by this paper
• 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

  2006cited by this paper
• Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.

  2006cited by this paper
• Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

  2005cited by this paper
• Adjuvant docetaxel for node-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.

  2003cited by this paper
• Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

  2003cited by this paper
• Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial.

  2002cited by this paper
• Small-cell lung cancer: patients included in clinical trials are not representative of the patient population as a whole.

  1999cited by this paper

• PRO Hair Safe Study: The Patient’s Perspective on the Effects of Scalp Cooling on Hair Preservation

  2023cites this paper
• Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study

  2022cites this paper
• E�cacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: A multi-center prospective observational study

  2022cites this paper
• Cells to Surgery Quiz: June 2021.

  2021cites this paper
• A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia

  2021cites this paper
• Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial

  2020cites this paper
• Real-World Costs of Azacitidine Treatment in Patients With Higher-Risk Myelodysplastic Syndromes/Low Blast-Count Acute Myeloid Leukemia.

  2020cites this paper
• A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.

  2020cites this paper
• Patients with metastatic melanoma receiving anticancer drugs: changes in overall survival, 2010-2017.

  2020cites this paper
• Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin’s lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study

  2018cites this paper
• Toxicities Associated with Docetaxel-Based Regimens in the Adjuvant Treatment of Early-Stage Breast Cancer: A Multicenter Prospective Real-Life Experience

  2018cites this paper
• A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer

  2018cites this paper
• Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens (ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer (REaCT-TC)

  2018cites this paper
• Relative dose intensity as a proxy measure of quality and prognosis in adjuvant chemotherapy for breast cancer in daily clinical practice.

  2017cites this paper
• Adjuvant chemotherapy in early breast cancer.

  2016cites this paper
• Interpreting febrile neutropenia rates from randomized, controlled trials for consideration of primary prophylaxis in the real world: a systematic review and meta-analysis.

  2016cites this paper
• Rates of major complications during neoadjuvant and adjuvant chemotherapy for early breast cancer: An off study population.

  2016cites this paper
• The Oncologist and the Intensivist : Bringing out the Meaning of Therapeutic Alliance

  2016cites this paper
• L’oncologue et le réanimateur : donner du sens à l’alliance thérapeutique

  2016cites this paper
• A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results

  2015influential citation
• Do participants in adjuvant breast cancer trials reflect the breast cancer patient population?

  2015cites this paper
• Risk of febrile neutropenia in patients receiving emerging chemotherapy regimens

  2014influential citation
• Characteristics of advanced cancer patients with cancer-related fatigue enrolled in clinical trials and patients referred to outpatient palliative care clinics.

  2013cites this paper
• Real-world impact of granulocyte-colony stimulating factor on febrile neutropenia.

  2013cites this paper
• Primary G-CSF prophylaxis for adjuvant TC or FEC-D chemotherapy outside of clinical trial settings: a systematic review and meta-analysis

  2012influential citation
• Arthralgies, effets secondaires des inhibiteurs de l’aromatase: fréquence, signification et conséquences

  2012cites this paper
• The high cost of cancer drugs and what we can do about it.

  2012cites this paper
• Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis

  2012cites this paper
• Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)

  2011cites this paper
• UvA-DARE ( Digital Academic Repository ) Recalcitrant chronic rhinosinusitis . Difficulties in diagnosis and treatment

  2011cites this paper
• Striking a balance between idealism and fatalism.

  2011cites this paper
• Delivering affordable cancer care in high-income countries.

  2011cites this paper
• Recalcitrant chronic rhinosinusitis. Difficulties in diagnosis and treatment

  2011cites this paper